(14/14) I leave you with my take-home slide from #AHA25. There are some reasons for optimism with coramitug and the ATTR antibody depleters – but this is hardly an unequivocal win or the “holy grail”. Let’s see what we learn with time – and more data.

Small number of patients, but good looking data from ATTRibute-CM on efficacy of acoramidis in the ATTRv amyloidosis population https://t.co/bY37MoXp32

Proud to be part of this

@JCardFail @KMAlexanderMD @AqamarMD @robmentz @dranulala @HFSA @AshishCorrea @elenadonaldMD @AndrewJSauer @ShashankSinhaMD @DrMarthaGulati

This was fun to do with Dan Judge, @MasriAhmadMD @KMAlexanderMD

Honored to present “Transplant Care in Non-Transplant Centers – The Hawaiian Experience” at the Stanford San Francisco Heart Transplant Summit 2025. Proud to share how Hawai‘i’s shared-care model extends transplant-level outcomes across 2,500 miles of ocean. 🌺 @HFSA @ISHLT

Acoramidis 📉 cumulative CV outcomes in #ATTRCM vs placebo, w/ numerical differences by month 1 & 📈 through month 30 (53 events avoided/100 pts). Nearly 1/4 of events occurred in the first 6 months, underscoring the need for timely Tx https://t.co/MOo8sZYmtF #HFSA2025 #JACC

@KMAlexanderMD presents data on acoramidis reduction of CV mortality/outcomes in ATTRibute and its OLE #ESC2025 #CardioTwitter #MedIQESCCongress

High Sensitivity Troponin for Contemporary Risk Stratification in Wild-Type ATTR Amyloidosis @KMAlexanderMD #AHAJournals

Read our latest contemporary review on polygenic risk in venous thromboembolism. Polygenic risk score improves risk prediction, guides anticoagulant use, and helps tailor prevention. @AqamarMD @MananPareekMD @KMAlexanderMD Link:

Proud to share our review on transthyretin amyloid cardiomyopathy! https://t.co/giACwEptSR We break down the current treatments, what’s in the pipeline, and what’s next. @UreyTony @UCSDCardiology

Another disappointment for #AL #amyloidosis #depleters: CARES didn’t meet its primary endpoint. What exactly was the prespecified subgroup that showed benefit? 🤔 Does this mean anything for #ATTR depleters? Time (and full data) will tell.

🎉 Kudos to Dr. Alexander for an outstanding presentation! 🧩 The "Thick Heart Puzzle" — Cardiac Amyloidosis vs. HCM. Insightful, impactful, and eye-opening! ❤️🩺 #InnovationsincardiologyHawaii @KMAlexanderMD

🥳🙌 Congratulations to @Stanford_HF's graduating HF fellows Ibrahim Alfaris, Leon Zhou, and Ricardo Chi Li! Great work and best of luck‼️ @KiranKhush1 @SunnyVMD @EldrinL @alyelezaby @KMAlexanderMD @stanfordctsurg @euanashley @Ron_Witteles @ATSandhu @vnparikh @ISHLT @HFSA

New research featuring #StanDOM's @graciafahed, @KMAlexanderMD, @Ron_Witteles, Francois Haddad & Gabriela Spencer-Bonilla, highlights how socioeconomic disparities hinder early detection of transthyretin cardiac amyloidosis. https://t.co/Cfxe3bk3Oz

👑 @MariannaFonta11 new data at #HeartFailure2025 from #ATTRibuteCM Exploring effects of acoramidis on functional capacity & QOL in patients with variant ATTR-CM 6-minute walking distance - 87m (!) mean increase KCCQ health status gain - 20pt (!) mean increase #MedIQHF2025

How do patients with #ATTRCM die? New insights from #ATTRibuteCM at #HeartFailure2025 @KMAlexanderMD @MasriAhmadMD #MedIQHF2025

New data from #ATTRibuteCM presented at #HeartFailure2025 Intriguing analysis by @KMAlexanderMD High-affinity TTR stabilizer acoramidis potentially associated with lower risks of AF/AFL events in #ATTRCM #MedIQHF2025

Establishing repeatability, reproducibility, & accuracy of imaging metrics is paramount for use in pivotal multicenter #amyloidosis trials. https://t.co/iShF56NNLn #JACCIMG #cvImaging #CardioTwitter #CardioOnc @DorbalaSharmila @KMAlexanderMD @MicheleEmdin

Incredibly proud of the ⁦@Stanford_HF⁩ team, with so many impactful presentations at #ISHLT2025. Honored to work with such a talented group! ⁦@JeffTeuteberg⁩ ⁦@ErikHenricksen⁩ ⁦@CODonnell1130⁩ ⁦@KMAlexanderMD⁩